Accent Microcell Ltd IPO

About Accent Microcell Ltd

The Company was originally incorporated on April 10, 2012 as a Private Limited Company as Accent Microcell Private Limited vide Registration No. 069799 under the provisions of the Companies Act, 1956 with the Registrar of Companies, Gujarat, Dadra and Nagar Haveli. Subsequently, pursuant to a special resolution passed by the Shareholders at their Extraordinary General Meeting held on December 05, 2022, the Company was converted from a Private Limited Company to Public Limited Company and consequently, the name of the Company was changed to Accent Microcell Limited and a Fresh Certificate of Incorporation consequent to Conversion was issued on December 23, 2022 by the Registrar of Companies, Ahmedabad. The Corporate Identification Number of the Company is U24230GJ2012PLC069799.

Pharmaceuticals Market size was valued at USD 209.85 billion in 2021 and is poised to grow from USD 222.4 billion in 2022 to USD 352.98 billion by 2030, growing at a CAGR of 5.9% in the forecast period (2023-2030). With about 46% of the market share, North America was the largest market for pharmaceuticals in the global pharmaceuticals market in 2021. The Asia Pacific was the second largest region making up more than 26% of the global pharmaceuticals market. Although the need for medicines is much greater in Africa, it holds the smallest market share in the global pharmaceuticals market. The Indian Pharmaceutical industry is currently ranked third in pharmaceutical production by volume after evolving over time into a thriving industry growing at a CAGR of 9.43% since the past nine years. Generic drugs, over-the-counter medications, bulk drugs, vaccines, contract research & manufacturing, biosimilars, and biologics are some of the major segments of the Indian pharma industry. India has the greatest number of pharmaceutical manufacturing facilities that are in compliance with the US Food and Drug Administration (USFDA) and has 500 API producers that make for around 8% of the worldwide API market. Market size of India pharmaceuticals industry is expected to reach US$ 65 billion by 2024, and ~US$ 130 billion by 2030. According to the government data, the Indian pharmaceutical industry is worth approximately US$ 50 billion with over US$ 25 billion of the value coming from exports. About 20% of the global exports in generic drugs are met by India.

The company was incorporated on April 10, 2012, with the primary focus on manufacturing of the high-quality cellulose-based excipients which predominantly find application in the Pharmaceutical, Nutraceutical, Food, Cosmetic and other industries. - the company manufactures cellulose-based excipients as follows: - Microcrystalline Cellulose (MCC) - Spray Dryer / Spin Flash Dried. - Microcrystalline Cellulose Spheres (MCC Spheres). - Silicified Microcrystalline Cellulose (SMCC). - Powdered Cellulose (PC). - Croscarmellose Sodium (CCS). - Magnesium Stearate (Mg. St.). - Microcrystalline Cellulose with Carboxy Methyl Cellulose (Co-Processed). Presently, the company majorly manufactures Microcrystalline Cellulose (MCC). MCC is an odourless, fine white powder & a purified form of cellulose, which is derived from refinement of highly purified wood pulp. It is widely used as texturizer, anticaking agent, binder, lubricant, a bulking agent, diluent which finds a wide range of applications in Pharmaceutical, Nutraceutical, Food, Cosmetic and other industries. The company manufactures 22 grades of MCC, with particle sizes ranging from 20 microns to 180 microns. The major grades of MCC manufactured and marketed by the Company are branded under the name accel. Besides accel the company also sells its products under the name acrocell, maccel and Vincel.

Strengths

Risk

Strategy